Skip to main content
. 2014 Jun 3;9(4):412. doi: 10.1007/s12263-014-0412-8

Table 1.

Characteristics of study participants at baseline by randomised treatment

Placebo 0.45 g/day 0.9 g/day 1.8 g/day P*
n = 70 n = 80 n = 80 n = 80
Gender
 Male, n (%) 31, 44 30, 37.5 30, 37.5 29, 36
 Female, n (%) 39, 56 50, 62.5 50, 62.5 51, 64
Ethnicity
 White, n (%) 57, 81.4 64, 80.0 64, 80.0 69, 86.25
 Far Eastern, n (%) 6, 8.6 4, 5.0 5, 6.25 1, 1.25
 S. Asian, n (%) 3, 4.3 6, 7.5 8, 10.0 1, 1.25
 Black, n (%) 2, 2.85 3, 3.75 0, 0.0 4, 5.0
 Other, n (%) 2, 2.85 3, 3.75 3, 3.75 5, 6.25
Age (years) 55.4 ± 6.9 55.1 ± 6.8 55.2 ± 6.6 55.1 ± 6.7 0.99
BMI (kg/m2) 26.1 ± 3.7 25.1 ± 3.9 26.2 ± 4.0 25.2 ± 3.5 0.17
Waist circumference (cm) 89.5 ± 11.7 87.3 ± 11.8 89.4 ± 11.9 88.0 ± 11.0 0.60
Plasma lipids (mmol/L)
 TC 5.4 ± 1.0 5.4 ± 1.1 5.4 ± 0.9 5.4 ± 1.0 0.94
 HDL-C 1.6 ± 0.5 1.6 ± 0.4 1.7 ± 0.5 1.7 ± 0.5 0.26
 LDL-C 3.3 ± 0.8 3.2 ± 0.8 3.2 ± 0.8 3.2 ± 0.7 0.79
 TGa 1.2 ± 0.5 1.1 ± 0.5 1.1 ± 0.4 1.1 ± 0.5 0.96

Data are presented for subjects randomised to treatment groups for whom DNA was available (n = 310). Measurements taken at baseline after 4-week run-in on normal diet with olive oil placebo supplement are shown for each randomised treatment group: placebo and EPA and DHA (1.51:1) at the daily doses shown. Values are n (%) for gender and ethnic groups, or mean ± SD for all other variables except TG

BMI body mass index, HDL-C high-density-lipoprotein cholesterol, LDL-C low-density-lipoprotein cholesterol, TC total cholesterol, TG triglyceride

* Significance of differences between treatment groups assessed by one-way ANOVA. P value for difference in age, adjusted for BMI, gender and ethnicity; for differences in BMI and waist circumference, adjusted for age, gender and ethnicity; for differences in plasma lipid concentrations, adjusted for BMI, age, gender and ethnicity

aTG data not normally distributed and presented as the geometric mean ± SE